Nektar Therapeutics

After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail
After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail
Fierce Biotech
Eli Lilly
Nektar Therapeutics
Rezpeg
lupus
Flag link:
Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment
Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment
Biopharma Reporter
Nektar Therapeutics
lupus
rezpegaldesleukin
layoffs
Rezpeg
Flag link:
After lupus setback, Nektar sticks with immunology but lays off 70% of hometown workforce
After lupus setback, Nektar sticks with immunology but lays off 70% of hometown workforce
Fierce Biotech
Nektar Therapeutics
reorganization
layoffs
Flag link:
Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink
Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink
Fierce Biotech
Nektar Therapeutics
rezpegaldesleukin
clinical trials
lupus
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
Nektar and PureTech merger talks called off
Nektar and PureTech merger talks called off
Pharmaforum
M&A
Nektar Therapeutics
PureTech
Flag link:
Nektar and Puretech make strange bedfellows
Nektar and Puretech make strange bedfellows
EP Vantage
Nektar Therapeutics
PureTech Health
M&A
Flag link:
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
BioSpace
ESMO
Bristol Myers Squibb
Nektar Therapeutics
Flag link:
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Fierce Biotech
Nektar Therapeutics
layoffs
Bristol Myers Squibb
Flag link:
Bristol Myers scraps $2B Nektar partnership after trial failures
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
Flag link:
BMS and Nektar Shutter Combination Cancer Development Program
BMS and Nektar Shutter Combination Cancer Development Program
BioSpace
Bristol Myers Squibb
Nektar Therapeutics
bladder cancer
renal cell carcinoma
bempegaldesleukin
Flag link:
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
Fierce Biotech
Bristol Myers Squibb
Opdivo
Nektar Therapeutics
bempegaldesleukin
clinical trials
Flag link:
Propel fails to propel Nektar
Propel fails to propel Nektar
EP Vantage
Nektar Therapeutics
Merck
bempegaldesleukin
clinical trials
metastatic non-small cell lung cancer
Flag link:
Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
Fierce Biotech
Sanofi
solid tumors
Bristol Myers Squibb
Nektar Therapeutics
Synthorx
clinical trials
Flag link:
Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Endpoints
Nektar Therapeutics
Bristol-Myers Squibb
NKTR-214
Flag link:
Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates
Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates
Endpoints
Nektar Therapeutics
Adynovate
Movantik
HealthCare Royalty Partners
Flag link:
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Fierce Biotech
melanoma
Nektar Therapeutics
bempegaldesleukin
Flag link:
Nektar pulls NDA for pain drug after unanimous AdComm rejection
Nektar pulls NDA for pain drug after unanimous AdComm rejection
Fierce Biotech
Nektar Therapeutics
opioids
FDA
oxycodegol
Flag link:
Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee
Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee
Motley Fool
Nektar Therapeutics
FDA
oxycodegol
painkillers
Flag link:
Nektar shows durability of Opdivo combo in 18-month update
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
Flag link:

Pages